Ankermann Tobias, Brehler Randolf
Childrens Hospital, Städtisches Krankenhaus Kiel gGmbH, Kiel, and.
Department of Dermatology, University Hospital Münster, Germany.
Allergol Select. 2023 Mar 1;7:33-38. doi: 10.5414/ALX02332E. eCollection 2023.
. Allergen immunotherapy (AIT) as a validated, disease-modifying treatment is nowadays a widely recommended therapy option for allergic rhinitis and allergic asthma. The registration of allergen extracts used for AIT is based on allergen standardization, dose finding trials, and phase 3 trials proving their efficacy in high-quality, statistically significant randomized clinical trials. Real-world evidence (RWE) studies confirm the clinical relevance of these findings. The most data are available for the treatment of patients suffering from allergic rhinitis. Due to the similar inflammatory mechanisms, allergic rhinitis is often associated with allergic asthma. AIT, which induces tolerance against individual allergens, is the approach to treat the underlying mechanisms of these two interrelated respiratory diseases. Some trials have been published focusing primarily on the effect of AIT on parameters of allergic asthma. Here we give a summary of the evidence for the efficacy of AIT in the indication of allergic asthma.
变应原免疫疗法(AIT)作为一种经过验证的疾病修正疗法,如今是过敏性鼻炎和过敏性哮喘广泛推荐的治疗选择。用于AIT的变应原提取物的注册基于变应原标准化、剂量探索试验以及在高质量、具有统计学意义的随机临床试验中证明其疗效的3期试验。真实世界证据(RWE)研究证实了这些发现的临床相关性。关于治疗过敏性鼻炎患者的数据最为丰富。由于炎症机制相似,过敏性鼻炎常与过敏性哮喘相关。诱导对个体变应原产生耐受性的AIT是治疗这两种相关呼吸道疾病潜在机制的方法。已经发表了一些主要关注AIT对过敏性哮喘参数影响的试验。在此,我们总结AIT在过敏性哮喘适应症中疗效的证据。